ANJ810

ANJ810 is a highly potent, selective small-molecule inhibitor of the anti-apoptotic protein myeloid cell leukemia 1 (MCL1), developed for the treatment of MCL1-dependent solid and hematologic malignancies. It is a macrocyclic MCL1 inhibitor designed with high biochemical and cellular potency against MCL1, while sparing other BCL-2 family members and minimizing cardiotoxicity through a rapid-clearance pharmacokinetic profile optimized to limit sustained target engagement in normal tissues.[1][5][7][9] Discovered through a structure-guided collaboration between the Broad Institute and Bayer and later advanced by Anji Pharma’s oncology-focused subsidiary Trueline Therapeutics, ANJ810/TTX-810 has demonstrated robust anti-tumor activity across MCL1-dependent cancer cell lines and xenograft models, with biomarker work suggesting that high BAK and low BCL-XL expression correlate with sensitivity.[1][5][7][9] The program has completed IND-enabling studies but has not progressed to late-stage clinical development and is reported as discontinued in public R&D databases.[3][11]